Business Wire

Alcresta Therapeutics Announces that RELiZORB® iMMOBILIZED LIPASE CARTRIDGE has been Issued a Permanent Medicare Billing Code (B4105) by the Centers for Medicare and Medicaid ...

WARREN, N.J.--(BUSINESS WIRE)--Alcresta Therapeutics, Inc. announced the issuance of a permanent and unique billing code by the Centers for Medicare and Medicaid Services (CMS) for RELiZORB. RELiZORB ...
Monthly Prescribing Reference

FDA Clears Digestive Enzyme Cartridge RELiZORB for Kids as Young as 1 Year

RELiZORB is a digestive enzyme cartridge designed to hydrolyze fats contained in enteral formulas, mimicking the function of lipase. The Food and Drug Administration (FDA) has expanded the approval of ...
Yahoo Finance

Alcresta Therapeutics Announces FDA Expanded Use Clearance for RELiZORB® (iMMOBILIZED LIPASE) Cartridge for Pediatric Patients 1 Year of Age and Older

WALTHAM, Mass., Jan. 15, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced ...
Medindia

Alcresta Therapeutics Announces FDA Clearance for the Next-Generation RELiZORB® Digestive Enzyme Cartridge

Next-generation RELiZORB technology expands device utility to support more patients including many living with SBS and other rare diseases. "Tube-fed patients have a wide range of enteral nutrition ...
Morningstar

Alcresta Therapeutics Announces Publication of Real-World Evidence Showing Improvements in Growth for Children Ages 1 to 5 Years Old With Use of RELiZORB®

RELiZORB was recently FDA cleared for use in patients of all ages, expanding the age indication to include neonates and infants. The clearance was supported by a retrospective evaluation of real-world ...
Yahoo Finance

Alcresta Therapeutics Announces Enrollment of First Patient in Clinical Trial Evaluating Use of RELiZORB in Critical Care Patients at Inova Fairfax Medical Campus

WALTHAM, Mass., June 16, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced ...
Business Wire

Alcresta Therapeutics Announces Publication of Consensus Statement Supporting Access to RELiZORB ®

WARREN, N.J.--(BUSINESS WIRE)--Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the publication of a ...
Monthly Prescribing Reference

Relizorb Approved to Improve Fat Absorption in Enteral Feeders

Alcresta has received de novo approval from the FDA to market Relizorb (immobilized lipase), a first-of-its kind digestive enzyme cartridge that breaks down fats in enteral tube feeding formula to ...
Pharmabiz

Alcresta Therapeutics announces MGH enrols first patient in clinical trial evaluating use of RELiZORB in pancreatitis patients

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, announced that Massachusetts General Hospital (MGH) has enrolled ...
KRQE Blogs

Alcresta Therapeutics Announces FDA Clearance for the Next-Generation RELiZORB® Digestive Enzyme Cartridge

Next-generation RELiZORB technology expands device utility to support more patients including many living with SBS and other rare diseases. WALTHAM, Mass., Dec. 21, 2023 /PRNewswire/ -- Alcresta ...
Pharmabiz

Alcresta announces publication of real-world evidence showing improvements in growth for children ages 1 to 5 years old with use of RELiZORB

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, announced the publication of real-world evidence results of ...